Sanofi-GSK COVID-19 vaccine booster yields stronger result than Pfizer’s in trial

In a phase 2/3 study, Sanofi-GSK’s next-generation COVID-19 vaccine booster resulted in 76.1 percent of participants seeing at least a tenfold increase in neutralizing antibody titers. Pfizer’s booster and Sanofi-GSK’s first-generation vaccine trailed behind at 63.2 percent and 55.3 percent, respectively, according to the June 13 press release. 

Advertisement
By: Paige Twenter

Among 247 study participants, the vaccine booster candidate proved effective against variants of concern 15 days after immunization.

The results are pending publication in a peer-reviewed journal, and the company plans to pitch the data to regulators in a few weeks.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.